114 / 119
113
Diretrizes AMB
phase III clinical trials. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):851-
7. PubMed PMID: 21521375.
33. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC,
Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly
improves symptoms of anxiety, depression, and skin-related quality of
life in patients with moderate-to-severe psoriasis: Results from a
randomized, double-blind, placebo-controlled phase III trial. J Am Acad
Dermatol. 2010 Sep;63(3):457-65. PubMed PMID: 20462664.